Decision Diagnostics 

$0.000100
7
+$0.00+0% Monday 20:00

Statistics

Day High
0.0001
Day Low
0.0001
52W High
0.0001
52W Low
0.0001
Volume
2,000,000
Avg. Volume
0
Mkt Cap
35,787.1
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

30NovExpected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-0
-0
-0
0
Expected EPS
0
Actual EPS
0

Financials

-1,499.19%Profit Margin
Unprofitable
2015
2016
2017
2018
2019
2020
1.98MRevenue
-29.67MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DECN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbott Laboratories
ABT
Mkt Cap166.17B
Abbott Laboratories competes with DECN in the blood glucose monitoring market, offering similar diabetes care products.
Dexcom
DXCM
Mkt Cap27.49B
DexCom, Inc. specializes in continuous glucose monitoring (CGM) systems, directly competing with DECN's glucose testing solutions.
Tandem Diabetes Care
TNDM
Mkt Cap1.06B
Tandem Diabetes Care, Inc. offers insulin pumps and related diabetes management products, competing in the broader diabetes care market.
Medtronic
MDT
Mkt Cap106.49B
Medtronic plc provides a range of diabetes management products, including CGM systems and insulin pumps, competing with DECN's offerings.
Insulet
PODD
Mkt Cap11.39B
Insulet Corporation's Omnipod insulin management system competes in the insulin delivery market, relevant to DECN's diabetes care solutions.
Senseonics
SENS
Mkt Cap286.07M
Senseonics Holdings, Inc. offers implantable CGM systems, competing with DECN's non-invasive glucose monitoring products.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson, through its subsidiary LifeScan, competes in the blood glucose monitoring market, offering products that rival DECN's.
Rogers
ROG
Mkt Cap2.52B
Roche Holding AG offers diabetes care solutions, including glucose monitors and insulin pumps, competing in the same market as DECN.
Novo Nordisk
NVO
Mkt Cap223.19B
Novo Nordisk A/S, while primarily known for insulin, also competes in the diabetes care market with its range of products.
Bristol-Myers Squibb
BMY
Mkt Cap118.71B
Bristol-Myers Squibb Company, through its acquisition of MyoKardia, is involved in cardiovascular care, indirectly competing with DECN's focus on diabetes management as diabetes is a risk factor for cardiovascular diseases.

About

Decision Diagnostics Corp. (DECN), founded in 2000 and based in Westlake Village, California, specializes in developing electronic medical record (EMR) technologies primarily optimized for smartphones. The company provides a wide array of offerings, including both regulated and unregulated diagnostic solutions, as well as home-use testing products for individuals managing chronic illnesses. They also facilitate direct-to-patient logistics for diabetes programs and concentrate on creating mobile-centric e-health products and associated technological innovations. A key part of their product line involves glucose monitoring. This includes the GenUltimate! glucose test strips, classified as a Class II medical device for personal at-home human use. For animal health, they manufacture PetSure! glucose test strips, designed to measure glucose levels in dogs and cats and compatible with legacy Zoetis AlphaTrak glucometers. Additionally, they offer the proprietary GenUltimate! 4Pets Glucose system, which combines the GenUltimate! 4Pets strip with the Avantage meter, enabling glucose testing for canine, feline, and equine patients. Further glucose strip options include GenUltimate! Sure and GenUltimate! Precis. Beyond product development, Decision Diagnostics actively acquires and maintains a portfolio of intellectual property, spanning patents, trademarks, and specialized manufacturing equipment. Their software solutions include MD@Hand, a comprehensive management system for both inpatient and outpatient care; Practice Probe, a data mining utility designed to extract information from physician practice management systems; and ResidenceWare, a residential management system that streamlines communication between commercial or residential real estate managers and their tenants through networked applications. Ultimately, their EMR innovations provide crucial tools for physicians directly at the point of patient care. The company was originally known as InstaCare Corp. before officially changing its name to Decision Diagnostics Corp. in November 2011.
Show more...
CEO
Mr. Keith M. Berman
Employees
6
Country
United States
ISIN
US2434431084

Listings

0 Comments

Share your thoughts

FAQ

What is Decision Diagnostics stock price today?
The current price of DECN is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Decision Diagnostics stock price performance more closely on the chart.
What is Decision Diagnostics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Decision Diagnostics stocks are traded under the ticker DECN.
Is Decision Diagnostics stock price growing?
DECN stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Decision Diagnostics has showed a +0% increase.
What is Decision Diagnostics market cap?
Today Decision Diagnostics has the market capitalization of 35,787.1
What were Decision Diagnostics earnings last quarter?
DECN earnings for the last quarter are 0 USD per share, whereas the estimation was 0 USD resulting in a +NaN% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Decision Diagnostics revenue for the last year?
Decision Diagnostics revenue for the last year amounts to 1.98M USD.
What is Decision Diagnostics net income for the last year?
DECN net income for the last year is -29.67M USD.
How many employees does Decision Diagnostics have?
As of July 10, 2026, the company has 6 employees.
In which sector is Decision Diagnostics located?
Decision Diagnostics operates in the Health & Wellness sector.
When did Decision Diagnostics complete a stock split?
Decision Diagnostics has not had any recent stock splits.
Where is Decision Diagnostics headquartered?
Decision Diagnostics is headquartered in Westlake Village, United States.